Rhodococcus is an emerging cause of opportunistic infection in immunocompromised patients, most commonly causing cavitary pneumonia. It has rarely been reported as a cause of isolated bacteremia. However, the relationship between bacteremia and central venous catheter is unknown. Between 2002 and 2010, the characteristics and outcomes of seventeen cancer patients with Rhodococcus bacteremia and indwelling central venous catheters were evaluated. Rhodococcus bacteremias were for the most part (94%) central line-associated bloodstream infection (CLABSI). Most of the bacteremia isolates were Rhodococcus equi (82%). Rhodococcus isolates formed heavy microbial biofilm on the surface of polyurethane catheters, which was reduced completely or partially by antimicrobial lock solution. All CLABSI patients had successful response to catheter removal and antimicrobial therapy. Rhodococcus species should be added to the list of biofilm forming organisms in immunocompromised hosts and most of the Rhodococcus bacteremias in cancer patients are central line associated.
References
[1]
Scott MA, Graham BS, Verrall R, Dixon R, Schaffner W, et al. (1995) Rhodococcus equi–an increasingly recognized opportunistic pathogen. Report of 12 cases and review of 65 cases in the literature. Am J Clin Pathol 103: 649–655.
[2]
Perez MG, Vassilev T, Kemmerly SA (2002) Rhodococcus equi infection in transplant recipients: a case of mistaken identity and review of the literature. Transpl Infect Dis 4: 52–56.
[3]
Goodfellow M, Alderson G (1977) The actinomycete-genus Rhodococcus: a home for the “rhodochrous” complex. J Gen Microbiol 100: 99–122.
Roda RH, Young M, Timpone J, Rosen J (2009) Rhodococcus equi pulmonary-central nervous system syndrome: brain abscess in a patient on high-dose steroids–a case report and review of the literature. Diagn Microbiol Infect Dis 63: 96–99.
[6]
Weinstock DM, Brown AE (2002) Rhodococcus equi: an emerging pathogen. Clin Infect Dis 34: 1379–1385.
[7]
Scotton PG, Tonon E, Giobbia M, Gallucci M, Rigoli R, et al. (2000) Rhodococcus equi nosocomial meningitis cured by levofloxacin and shunt removal. Clin Infect Dis 30: 223–224.
[8]
Gray KJ, French N, Lugada E, Watera C, Gilks CF (2000) Rhodococcus equi and HIV-1 infection in Uganda. J Infect 41: 227–231.
[9]
Chen XY, Xu F, Xia JY, Cheng YS, Yang Y (2009) Bacteremia due to Rhodococcus equi: a case report and review of the literature. J Zhejiang Univ Sci B 10: 933–936.
[10]
Hsueh PR, Hung CC, Teng LJ, Yu MC, Chen YC, et al. (1998) Report of invasive Rhodococcus equi infections in Taiwan, with an emphasis on the emergence of multidrug-resistant strains. Clin Infect Dis 27: 370–375.
[11]
Cid A, Jarque I, Salavert M, Martin G, Perez-Belles C, et al. (2002) Recurrent bacteremia caused by Rhodococcus equi in a non-neutropenic patient with acute myeloid leukemia in complete remission. Haematologica 87: ECR03.
[12]
Langer AJ, Feja K, Lasker BA, Hinrikson HP, Morey RE, et al. (2010) Investigation of an apparent outbreak of Rhodococcus equi bacteremia. Diagn Microbiol Infect Dis 67: 95–100.
[13]
Baba H, Nada T, Ohkusu K, Ezaki T, Hasegawa Y, et al. (2009) First case of bloodstream infection caused by Rhodococcus erythropolis. J Clin Microbiol 47: 2667–2669.
[14]
Guerrero R, Bhargava A, Nahleh Z (2011) Rhodococcus equi venous catheter infection: a case report and review of the literature. J Med Case Reports 5: 358.
[15]
Verville TD, Huycke MM, Greenfield RA, Fine DP, Kuhls TL, et al. (1994) Rhodococcus equi infections of humans. 12 cases and a review of the literature. Medicine (Baltimore) 73: 119–132.
[16]
DeMarais PL, Kocka FE (1995) Rhodococcus meningitis in an immunocompetent host. Clin Infect Dis 20: 167–169.
[17]
Gopaul D, Ellis C, Maki A Jr, Joseph MG (1988) Isolation of Rhodococcus rhodochrous from a chronic corneal ulcer. Diagn Microbiol Infect Dis 10: 185–190.
[18]
von Below H, Wilk CM, Schaal KP, Naumann GO (1991) Rhodococcus luteus and Rhodococcus erythropolis chronic endophthalmitis after lens implantation. Am J Ophthalmol 112: 596–597.
[19]
Kedlaya I, Ing MB, Wong SS (2001) Rhodococcus equi infections in immunocompetent hosts: case report and review. Clin Infect Dis 32: E39–46.
[20]
Torres-Tortosa M, Arrizabalaga J, Villanueva JL, Galvez J, Leyes M, et al. (2003) Prognosis and clinical evaluation of infection caused by Rhodococcus equi in HIV-infected patients: a multicenter study of 67 cases. Chest 123: 1970–1976.
[21]
Munoz P, Palomo J, Guinea J, Yanez J, Giannella M, et al. (2008) Relapsing Rhodococcus equi infection in a heart transplant recipient successfully treated with long-term linezolid. Diagn Microbiol Infect Dis 60: 197–199.
[22]
Raad I, Hanna H, Jiang Y, Dvorak T, Reitzel R, et al. (2007) Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 51: 1656–1660.
[23]
Raad I, Hanna H, Dvorak T, Chaiban G, Hachem R (2007) Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm. Antimicrob Agents Chemother 51: 78–83.
[24]
Raad I, Bodey GP (2011) Editorial: Novel antimicrobial catheter lock solution: A new direction where chelators replace heparin. . Crit Care Med In press 39:
[25]
Safdar N, Maki DG (2006) Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infection associated with central venous access devices: a meta-analysis of prospective, randomized trials. Clin Infect Dis 43: 474–484.
[26]
Maki DG, Ash SR, Winger RK, Lavin P (2010) A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: A multi-center, controlled, randomized trial. Crit Care Med.
[27]
Chandra J, Mukherjee PK, Appelt K, Lanzilotti M, Ghannoum MA (2008) B-lock containing Ca-EDTA exhibits wide-spectrum activity against multidrug-resistant bacteria and fungi. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America 46th Annual Meeting. Washington, D.C., October 25–28.
[28]
Chandra J, Mukherjee PK, Appelt K, Lanzilotti M, Ghannoum MA (2008) Antibiofilm activity of B-lock compared to citrate-based lock therapy. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America 46th Annual Meeting. Washington, D.C., October 25–28.
[29]
O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, et al. (2011) Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 52: e162–193.
[30]
Mermel LA, Farr BM, Sherertz RJ, Raad , O'Grady N, et al. (2001) Guidelines for the management of intravascular catheter-related infections. Infect Control Hosp Epidemiol 22: 222–242.
[31]
Halbert ND, Reitzel RA, Martens RJ, Cohen ND (2005) Evaluation of a multiplex polymerase chain reaction assay for simultaneous detection of Rhodococcus equi and the vapA gene. Am J Vet Res 66: 1380–1385.
[32]
Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA (2002) Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 46: 1773–1780.
[33]
Chaiban G, Hanna H, Dvorak T, Raad I (2005) A rapid method of impregnating endotracheal tubes and urinary catheters with gendine: a novel antiseptic agent. J Antimicrob Chemother 55: 51–56.
